Department of Clinical Oral Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8588, Japan.
Department of Oral Oncology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan.
Int J Environ Res Public Health. 2023 Mar 3;20(5):4545. doi: 10.3390/ijerph20054545.
There are a few reports that focus on radiotherapy (RT) and cetuximab (CET) therapy exclusively for oral cancer. This retrospective study aimed to investigate the efficacy and safety of RT and CET therapy for locally advanced (LA) or recurrent/metastatic (R/M) oral squamous cell carcinoma (OSCC). Seventy-nine patients from 13 hospitals who underwent RT and CET therapy for LA or R/M OSCC between January 2013 and May 2015 were enrolled in the study. Response, overall survival (OS), disease-specific survival (DSS), and adverse events were investigated. The completion rate was 62/79 (78.5%). The response rates in patients with LA and R/M OSCC were 69% and 37.8%, respectively. When only completed cases were examined, the response rates were 72.2% and 62.9%, respectively. The 1- and 2-year OS were 51.5% and 27.8%, respectively (median, 14 months), for patients with LA OSCC, and 41.5% and 11.9% (median, 10 months) for patients with R/M OSCC. The 1- and 2-year DSS were 61.8% and 33.4%, respectively (median, 17 months), for patients with LA OSCC, and 76.6% and 20.4% (median, 12 months) for patients with R/M OSCC. The most common adverse event was oral mucositis (60.8%), followed by dermatitis, acneiform rash, and paronychia. The completion rate was 85.7% in LA patients and 70.3% in R/M patients. The most common reason for noncompletion was an inadequate radiation dose due to worsening general conditions in R/M patients. Although the standard treatment for LA or R/M oral cancer is concomitant RT with high-dose cisplatin (CCRT) and the efficacy of RT and CET therapy for oral cancer is not considered to be as high as that for other head and neck cancers, it was thought that RT and CET therapy could be possible treatments for patients who cannot use high-dose cisplatin.
有一些报告专门关注放疗 (RT) 和西妥昔单抗 (CET) 治疗口腔癌。本回顾性研究旨在探讨 RT 和 CET 治疗局部晚期 (LA) 或复发性/转移性 (R/M) 口腔鳞状细胞癌 (OSCC) 的疗效和安全性。本研究纳入了 2013 年 1 月至 2015 年 5 月期间在 13 家医院接受 RT 和 CET 治疗的 79 例 LA 或 R/M OSCC 患者。对患者的反应、总生存期 (OS)、疾病特异性生存期 (DSS) 和不良反应进行了调查。79 例患者中，有 62 例（78.5%）完成了治疗。LA 和 R/M OSCC 患者的反应率分别为 69%和 37.8%。仅分析完成病例时，反应率分别为 72.2%和 62.9%。LA OSCC 患者的 1 年和 2 年 OS 率分别为 51.5%和 27.8%（中位 14 个月），R/M OSCC 患者的 1 年和 2 年 OS 率分别为 41.5%和 11.9%（中位 10 个月）。LA OSCC 患者的 1 年和 2 年 DSS 率分别为 61.8%和 33.4%（中位 17 个月），R/M OSCC 患者的 1 年和 2 年 DSS 率分别为 76.6%和 20.4%（中位 12 个月）。最常见的不良反应是口腔黏膜炎（60.8%），其次是皮炎、痤疮样皮疹和甲周炎。LA 患者的完成率为 85.7%，R/M 患者的完成率为 70.3%。R/M 患者未完成治疗的最常见原因是由于一般状况恶化而导致放疗剂量不足。尽管 LA 或 R/M 口腔癌的标准治疗方法是同时进行高剂量顺铂放化疗（CCRT），且 RT 和 CET 治疗口腔癌的疗效不如其他头颈部癌症，但人们认为 RT 和 CET 治疗可能是那些不能使用高剂量顺铂的患者的一种可行治疗方法。
